Markus Kupka
Overview
Explore the profile of Markus Kupka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, Cuevas Saiz I, et al.
Hum Reprod
. 2023 Oct;
38(12):2321-2338.
PMID: 37847771
Study Question: What are the data and trends on ART and IUI cycle numbers and their outcomes, and on fertility preservation (FP) interventions, reported in 2019 as compared to previous...
2.
Banker M, Dyer S, Chambers G, Ishihara O, Kupka M, de Mouzon J, et al.
Fertil Steril
. 2021 Apr;
116(3):741-756.
PMID: 33926722
Objective: To report the utilization, effectiveness, and safety of practices in assisted reproductive technology (ART) globally in 2013 and assess global trends over time. Design: Retrospective, cross-sectional survey on the...
3.
Dyer S, Chambers G, Adamson G, Banker M, de Mouzon J, Ishihara O, et al.
Reprod Biomed Online
. 2020 Oct;
41(6):1158.
PMID: 33032907
No abstract available.
4.
de Mouzon J, Chambers G, Zegers-Hochschild F, Mansour R, Ishihara O, Banker M, et al.
Hum Reprod
. 2020 Jul;
35(8):1900-1913.
PMID: 32699900
Study Question: What was the utilization, effectiveness and safety of practices in ART globally in 2012 and what global trends could be observed? Summary Answer: The total number of ART...
5.
Dyer S, Chambers G, Adamson G, Banker M, de Mouzon J, Ishihara O, et al.
Reprod Biomed Online
. 2020 May;
41(1):6-9.
PMID: 32448672
This commentary outlines the importance of utilizing assisted reproductive technology (ART) as an indicator of access to infertility care and provides a standard way of reporting utilization to facilitate international...
6.
Engelstaedter V, Heublein S, Schumacher A, Lenhard M, Engelstaedter H, Andergassen U, et al.
BMC Cancer
. 2012 Dec;
12:600.
PMID: 23241107
Background: Mucin-1 is known to be over-expressed by various human carcinomas and is shed into the circulation where it can be detected in patient's serum by specific anti-Mucin-1 antibodies, such...
7.
Jeschke U, Wiest I, Schumacher A, Kupka M, Rack B, Stahn R, et al.
Anticancer Res
. 2012 May;
32(5):2185-9.
PMID: 22593508
Aim: Mucin 1 (MUC1) is a high molecular weight transmembrane glycoprotein with unique properties which is used as a tumour marker in sera of ovarian cancer patients. The common test...
8.
Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer
Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, et al.
BMC Cancer
. 2012 Jan;
12:2.
PMID: 22214378
Background: An influence of gonadotropins (hCG) on the development of ovarian cancer has been discussed. Therefore, we quantified serum hCG levels in patients with benign and malignant ovarian tumors and...
9.
Pavlik R, Wypior G, Hecht S, Papadopoulos P, Kupka M, Thaler C, et al.
Histochem Cell Biol
. 2011 Aug;
136(3):289-99.
PMID: 21809103
Estradiol and progesterone mediate their actions by binding to classical nuclear receptors, estrogen receptor α (ERα) and estrogen receptor β (ERβ) and progesterone receptor A and B (PR-A and PR-B)...
10.
Lawrenz B, Jauckus J, Kupka M, Strowitzki T, von Wolff M
Fertil Steril
. 2010 Aug;
94(7):2871-3.
PMID: 20678763
Ovarian stimulation and cryopreservation of fertilized oocytes before cancer therapy is the best established and efficient fertility preservation technique and should still be considered before chemotherapy. Within a short time...